Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
University of Chicago
Icahn School of Medicine at Mount Sinai
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
University of Maryland, Baltimore
Istanbul Training and Research Hospital
University of Chicago
Mashhad University of Medical Sciences
Rochester Dermatologic Surgery
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
University of Pittsburgh
Indiana University
University of Pittsburgh
Gustave Roussy, Cancer Campus, Grand Paris
Stanford University
Replimune Inc.
Brigham and Women's Hospital
Federation Francophone de Cancerologie Digestive
Washington University School of Medicine
Sun Yat-sen University
ImmunityBio, Inc.
Federation Francophone de Cancerologie Digestive
Cairo University
Centre Hospitalier Universitaire, Amiens
Rigshospitalet, Denmark
Centre Hospitalier Universitaire Dijon
Peter MacCallum Cancer Centre, Australia
Baptist Health South Florida
Power Life Sciences Inc.
University of Kentucky
University of Kentucky
UMC Utrecht
Fondation Hôpital Saint-Joseph
Carilion Clinic
Karyopharm Therapeutics Inc
Istituto Clinico Humanitas
Centre Hospitalier Universitaire UCLouvain Namur
Sinocelltech Ltd.
Heidelberg University
Alpha Tau Medical LTD.
Centre Hospitalier Universitaire de Nice
UMC Utrecht
Stanford University
Assistance Publique - Hôpitaux de Paris
National University Hospital, Singapore
University of Zurich
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Vanderbilt-Ingram Cancer Center
Stanford University